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Abstract
Tauopathic pathways lead to degenerative changes in Alzheimer’s disease and there is evidence that they are also involved
in the neurodegenerative pathology of Parkinson’s disease [PD]. We have examined tauopathic changes in striatum of the a-
synuclein (a-Syn) A53T mutant mouse. Elevated levels of a-Syn were observed in striatum of the adult A53T a-Syn mice. This
was accompanied by increases in hyperphosphorylated Tau [p-Tau], phosphorylated at Ser202, Ser262 and Ser396/404,
which are the same toxic sites also seen in Alzheimer’s disease. There was an increase in active p-GSK-3b,
hyperphosphorylated at Tyr216, a major and primary kinase known to phosphorylate Tau at multiple sites. The sites of
hyperphosphorylation of Tau in the A53T mutant mice were similar to those seen in post-mortem striata from PD patients,
attesting to their pathophysiological relevance. Increases in p-Tau were not due to alterations on protein phosphatases in
either A53T mice or in human PD, suggesting lack of involvement of these proteins in tauopathy. Extraction of striata with
Triton X-100 showed large increases in oligomeric forms of a-Syn suggesting that a-Syn had formed aggregates the mutant
mice. In addition, increased levels of p-GSK-3b and pSer396/404 were also found associated with aggregated a-Syn.
Differential solubilization to measure protein binding to cytoskeletal proteins demonstrated that p-Tau in the A53T mutant
mouse were unbound to cytoskeletal proteins, consistent with dissociation of p-Tau from the microtubules upon
hyperphosphorylation. Interestingly, a-Syn remained tightly bound to the cytoskeleton, while p-GSK-3b was seen in the
cytoskeleton-free fractions. Immunohistochemical studies showed that a-Syn, pSer396/404 Tau and p-GSK-3b co-localized
with one another and was aggregated and accumulated into large inclusion bodies, leading to cell death of Substantia
nigral neurons. Together, these data demonstrate an elevated state of tauopathy in striata of the A53T a-Syn mutant mice,
suggesting that tauopathy is a common feature of synucleinopathies.
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Introduction
a-Synuclein (a-Syn) is expressed in the brain and is highly
enriched in presynaptic nigrostriatal nerve terminals, where its
chief physiological function may be the regulation of synaptic
levels of dopamine and other monoamines through modulation of
the monoamine transporters [1]. Overexpression of a-Syn,
through its gene duplication and triplication, is linked to idiopathic
Parkinson’s disease (PD), while its A30P and A53T mutants cause
the autosomal dominant forms of familial PD [2–4]. In
pathological states, a-Syn becomes misfolded, aggregates and
accumulates into neuronal inclusion bodies and Lewy bodies (LBs),
hallmarks of PD and other synucleinopathies [2,5–6]. Post-
mortem immunohistochemical studies show the presence of
hyperphosphorylated Tau (p-Tau), a protein normally linked to
the genesis of Alzheimer’s disease (AD), co-existing with a-Syn
aggregates in the same neurons in PD and other synucleinopathies
[7–14]. Conversely, in tauopathies such as AD, elevated levels of
a-Syn have been found [15–20], along with LBs [15,21,22]. More
recently, we have shown in human post-mortem PD striata that in
addition to elevated levels of insoluble aggregates of a-Syn, p-Tau
levels were also increased [23]. Thus, we found increases in p-Tau
hyperphosphorylated at Ser202, Ser262 and Ser396/404; these
are the same sites that are also primarily hyperphosphorylated in
AD, leading to pathological changes. In addition, we also found
increases in levels of active GSK-3b [p-GSK-3b, hyperpho-
sphorylated at Tyr216], the kinase known to hyperphosphorylate
Tau at the above mentioned sites. Together, these data suggest
that synucleinopathies and tauopathies may actually be overlap-
ping or interacting neurodegenerative diseases, rather than
distinct entities.
Using the MPTP mouse neurotoxin model of PD, as well as
cellular models of PD, we had previously demonstrated that
increases in a-Syn can initiate and sustain Tau hyperpho-
sphorylation both in vivo and in vitro [24–27]. The hyperpho-
sphorylation of Tau in our studies was absolutely dependent on the
presence of a-Syn, as indexed by lack of p-Tau formation in either
MPTP-treated a-Syn2/2 mice, or in toxin-treated neuronal cells
lacking a-Syn [24,27]. The underlying reason for the mandatory
requirement for a-Syn in formation of p-Tau is not clear, but our
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autophosphorylation at Tyr216 [26–27], suggesting a tight
interaction between a-Syn and p-GSK-3b is necessary for Tau
hyperphosphorylation. Moreover, when incubated together in vitro,
a-Syn may serve as a seed, accelerating the aggregation of Tau
[12].
We undertook the current investigation to analyze the state of
tauopathy in a transgenic mouse model of PD, the hemizygous
transgenic mice expressing the human a-Syn A53T mutant [28].
Tauopathic changes were observed in the striata of the A53T a-
Syn transgenic mice. Moreover, such changes were similar to those
found in striata of human PD patients. The A53T a-Syn was
aggregated, along with pSer396/404 Tau and p-GSK-3b. a-Syn
was found to be bound to the cytoskeleton, while pSer202,
pSer262 and pSer396/404 Tau and p-GSK-3b were present in
cytoskeletal-free fraction. Immunohistochemical studies showed
that a-Syn, p-Tau and p-GSK-3b co-localized with one another
and were accumulated into inclusion bodies.
Together, our studies indicate an elevated state of tauopathy in
striata of the A53T a-Syn mutant mice, reminiscent of that seen in
PD striata, lending further credence to our conclusion that
tauopathy is also a common feature of synucleinopathies.
Results
a-Syn, p-Tau and GSK-3b protein expression levels in
A53T mutant mouse
PIPES/SDS extracts of striatum from A53T a-Syn mutant mice
were recombined to obtain total extracts, as described in Methods.
and these extracts were examined by Western blots to assess
changes in proteins we have previously shown to be involved in the
tauopathic pathway in different PD models [24–27]. The
expression levels of a-Syn [Mr 17 kDa] were significantly
[P,0.05] increased by 75% in the A53T mutant mice [n=4],
as compared to litter-mate, age-matched wild-type animals [n=4,
Fig. 1A]. In addition, an increase [of 70%, n=4, P,0.05] in p-a-
Syn [Mr 16 kDa], detected by a phospho-specific antibody was
also detected in A53T mutant mice, as compared to wild type
litter-mate controls [Fig. 1A]. We also examined b-Syn levels [Mr
16,kDa] and found increased [58%, n=4, P,0.05] levels of this
protein in A53T mutant mice.
The overexpression of A53T a-Syn and b-Syn was accompa-
nied by an increase in p-Tau levels hyperphosphorylated at
different epitopes [Fig. 1B]. Thus, there was a significant [P,0.05]
increase of 204% in p-Tau hyperphosphorylated at Ser202 [Mr
55 kDa; n=6], along with a significant [P,0.05] increase of 36%
in pSer262 [Mr 60 kDa] in mutant mice [n=6], as compared to
wild-type mice [n=9]. Similarly, p-Tau hyperphosphorylated at
Ser396/404 [Mr 55 kDa], was also significantly [p,0.05]
increased by 349% in mutant mice as compared to wild-type
[n=6 and 9, respectively].
We next measured changes in p-GSK-3b, hyperphosphorylated
at Tyr216, a major kinase known to phosphorylate Tau [Fig. 1C].
The antibody against p-GSK-3b also recognizes p-GSK-3a,
detectable as a band of Mr ,50 kDa visible above p-GSK-3b;
in our studies, only the lower band, corresponding to p-GSK-3b
[Mr of 46 kDa] was used to calculate for levels of this protein. We
found significant [P,0.05] increases of 128% in the levels of p-
GSK-3b in mutant mice relative to wild-type animals [n=4 and 4,
respectively]. Moreover, a significant increase [of 45%] in levels of
the inactive form of GSK-3b, hyperphosphorylated at Ser9 [Mr
46 kDa], was also seen in striatum of the A53T mutant mouse. No
significant changes were observed in b-actin [Mr 43 kDa], total
Tau [bands with Mr of 52–68 kDa] or total GSK-3b [Mr 46 kDa]
between the two groups of mice. Together, these data indicate the
existence of an elevated state of tauopathy in striata of the A53T a-
Syn mutant mice.
To eliminate the possibility that decreases in protein phospha-
tases [PP] lead to an increase in p-Tau levels, we also examined
the levels of the major protein phosphatases found in brain, PP1
and PP2 [Fig. 1D]. There were no significant [P.0.05] differences
in the expression levels of PP1, PP2A or PP2B [Mr of 38, 62 and
55 kDa, respectively] between A53T or wild type controls, [n=6],
suggesting that increases in p-Tau were not due to decreases in
protein phosphatases.
Increase in p-Tau and p-GSK-3b in striata of postmortem
PD brains
In order to ascertain whether tauopathic changes in the A53T
mice resemble that seen in humans, we examined tauopathy in
striata from postmortem brains of PD patients. a-Syn levels were
measured in postmortem striata of 6 control subjects [Fig. 2A] and
from 6 patients clinically diagnosed with PD, as previously
described in Methods. In the PD patient samples tested, expression
levels of a-Syn were increased [208%, P,0.05], as compared to
age-matched controls. When we measured changes in p-a-Syn in
PD, we found significant [P,0.05] increases in the phosphorylated
protein [of 104%, n=7] in PD striata compared to non-diseased
controls.
We next examined p-Tau levels in the striata of controls and PD
patients [Fig. 2B]. There were no significant changes in total Tau
levels between control subjects and PD patients. However,
significant increases were observed for all p-Tau epitopes
measured. We found increases of 161% [P,0.05] in the levels
of Tau hyperphosphorylated at pSer202 in PD striata compared to
striata from control subjects [Fig. 2B]. Hyperphosphorylation of
Tau at pSer262 was increased by 72% [P,0.05] in striata of PD
patients relative to controls. Tau phosphorylation at pSer396/404
was increased by 128% [P,0.05] in PD striata relative to age-
matched controls [Fig. 2B]. Thus, significant increases in Tau
hyperphosphorylation are present at the same three epitopes in
human PD as those detected in A53T mutant mice.
We also analyzed p-GSK-3b levels in control and PD human
samples and found an increase of 128% [P,0.05] in PD brains
compared to age-matched controls [Fig. 2C].Thus, while the
absolute values of the increases vary between human PD and the
A53T mutant mouse, there is nonetheless an analogous pattern of
increase in a-Syn, p-Tau proteins, and p-GSK-3b, suggesting that
this animal model of PD shows similar tauopathy as human PD.
We next examined changes in PP levels in striatum of PD
[Fig. 2D]. There were no significant changes in levels of either
PP1, PP2A or PP2B between PD and control striata, similar to our
findings in A53T transgenic and wild type, again suggesting that
alterations in protein phosphatases do not contribute to increases
in p-Tau levels.
Triton X-100 solubilization of striatal proteins
Previous studies have shown a differential solubility of a-Syn in
1% Triton X-100, whereby aggregates of a-Syn were found to
segregate in Triton X-100-insoluble fractions upon centrifugation
[30]. To test whether aggregates of a-Syn were present in striata of
the A53T mutant mouse, striatal tissues were extracted in Triton
X-100, as described under Methods, and this protein was
examined in both soluble and insoluble fractions [Fig. 3A].
Compared to wild type non-transgenic animals [n=4], a-Syn
isolated from the A53T transgenic mice were increased in both
Triton X-100 soluble and insoluble extracts. Whereas the majority
of the a-Syn in Triton X-100-soluble extracts from wild type
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additional bands with Mr of ,24 and 35 kDa were present, along
with faint bands .38 kDa and a band below 17 kDa, with Mr of
,12 kDa. In the Triton X-100-insoluble fraction, a single band
corresponding to the monomeric form of the protein was observed
in the wild type animal [Fig. 3A]. In the transgenic A53T mice,
multiple bands were seen. Thus, strong bands of Mr of 12 and
24 kDa were seen; a 34 kDa band, likely representing a dimeric
form of the 17 kDa species was seen; a faint band at ,40 kDa was
seen. Finally, a prominent band at ,52 kDa was seen, which may
represent a trimeric form of the 17 kDa monomer.
The 14 kDa band is noteworthy in that it is only seen in the
A53T mutant and not in the wild type mice [see Figs. 1A, 3A and
4A]. Although it remains to be confirmed, this polypeptide may
represent either a truncated form of the full length a-Syn or,
alternatively, a degraded form of the 17 kDa protein. Regardless,
the results of Triton X-100 extractions suggests that this protein
aggregates capable of forming dimers of 28 kDa and trimers of
,40 kDa [see Fig. 3A].
When similar studies were conducted with p-GSK-3b [Fig. 3B],
we found no significant differences in the levels of p-GSK-3b in
the soluble fraction, whereas the levels of p-GSK-3b present in the
Triton X-100-insoluble fractions were increased by 98% [P,0.01,
n=4]. This finding was surprising, since p-GSK-3b is a soluble
protein, and its presence in the insoluble fraction suggests that it
has become aggregated and/or that a co-interaction of the kinase
with a-Syn must exist, causing it to co-segregate with a-Syn in the
insoluble fraction. Indeed, in earlier studies, using a MPTP-treated
mouse model which develops tauopathy, we have shown that
activated p-GSK-3b co-immunoprecipitates with a-Syn and with
pSer396/404 Tau [24].
When we examined p-Tau levels in the Triton X-100 soluble
and insoluble fractions [Fig. 3C], we found large significant
increases [124%, P,0.05, n=4] in pSer202 levels in the soluble
fraction in the A53T mice; this epitope was not detected in the
Triton X-100 insoluble fraction for either the transgenic or wild
type mouse. Significant increases were also seen for pSer262 in the
Triton X-100 soluble fraction [105%, P,0.05, n=4] in A53T
mice. Although a small increase in pSer262 was seen in Triton X-
100-insoluble fractions [Fig. 3C], this increase was not significant
[P.0.05]. In the Triton X-100-soluble fractions of A53T mice,
pSer396/404 Tau levels were significantly [P,0.05, n=4]
increased by 93%, whereas in the Triton X-100-insoluble fraction
it was increased by 112% [P,0.05, n=4] compared to wild type
animals. The presence of high levels of pSer396/404 in the Triton
X-100-insoluble fraction suggests its aggregation and/or interac-
tion with aggregated a-Syn.
Interactions of a-Syn, p-Tau epitopes and p-GSK-3b with
the cytoskeleton
Both a-Syn and Tau are microtubule binding proteins; in
addition, we have shown that a-Syn can also bind to the actin
cytoskeleton [31]. Upon hyperphosphorylation, p-Tau is known to
dissociate from microtubules. We therefore felt it worthwhile to
analyze how a-Syn and p-Tau interact with the cytoskeleton
proteins in the striatum of the A53T mutant mice. To conduct
these studies, striatal tissue was differentially extracted in PIPES
and SDS buffer, as described in Methods, to isolate cytoskeleton-
free and cytoskeleton-bound proteins, respectively.
Similar levels of a-Syn were seen in the PIPES-extracted
cytoskeleton-free fractions of A53T mice, as compared to wild-
type controls [Fig. 4A]. Interestingly, there was a large [90%] and
significant [P,0.05, n=4] increase in a-Syn levels observed in the
SDS-extracted cytoskeleton-bound fraction. In parallel studies
conducted with p-GSK-3b [Fig. 4A], increased levels [42%,
P,0.05, n=4] of this protein were observed in the cytoskeleton-
free fraction of A53T mice as compared to insignificant decreases
in the cytoskeleton-bound fraction. This finding is entirely
consistent with the fact that neither p-GSK-3b nor GSK-3b is
known to directly interact with cytoskeleton proteins.
When we examined p-Tau interactions with the cytoskeleton
[Fig. 4B]. pSer202 was exclusively detected only in the PIPES-
extracted, cytoskeleton-free fractions, and significant increases in
pSer202 were seen in these fractions in A53T mice [123%, n=4,
P,0.05]. Similarly, increases in pSer262 were seen in cytoskel-
eton-free fractions in A53T mice [27%, n=4, P,0.05]; a small
amount of pSer262 remained associated with the cytoskeleton
fraction, but there were no significant differences between wild
type and mutant mice. Finally for pSer396/404, increases in this
protein were seen in only in cytoskeleton-free fractions in extracts
from mutant mice [89%, n=4, P,0.05], while no differences
were detected between these mice and wild type mice. These
combined data suggest that upon hyperphosphorylation, Tau
dissociates from the cytoskeleton fraction.
Immunohistochemical co-localization and distribution in
striatum
The aggregation and co-localization of a-Syn with pGSK-3b
and p-Tau was analyzed by immunohistochemical [IHC] staining
of the striatum of A53T a-Syn mutant mice and compared to age-
matched wild-type mice [Fig. 5A–C]. An overall total increase in
levels of a-Syn, pGSK-3b, and p-Tau was seen in the striatum of
A53T a-Syn mice as compared to wild-type control striatum. Dual
staining was performed to analyze the co-localization of the
following protein combinations: a-Syn:p-Tau, a-Syn:p-GSK-3b
and p-Tau:p-GSK-3b. Each protein combination co-localized
together in a single large aggregate formation in the transgenic
striatum, as opposed to the multiple small puncta and more diffuse
cytoplasmic distribution seen in the WT striatum. This large
aggregate seen in the Tg striatum is reminiscent of pathogenic
Lewy bodies in shape, size, and cellular location.
Further IHC analysis examined the temporal loss of TH positive
cells in the striatum when comparing the striatal region in A53T
and wildtype mice [Fig. 6A]. A definitive loss of TH positive
neurons is observed in the striatum of Tg mice when compared to
WT. The TH antibody also shows a clear distinction between the
abundant TH-positive neuron containing striatum versus the
absence of such TH positive neurons in the cortex. To observe a
Figure 1. Elevated levels of a-Syn, p-Tau and p-GSK-3b in striata of a-Syn A53T mutant mice. Striata from wild type non-transgenic mice
and A53T a-Syn mutant transgenic mice, 8 months of age, were dissected and homogenized in RIPA buffer, and analyzed by Western blots, as
described under ‘‘Materials and Methods’’. After exposure to initial antibodies, blots were stripped and probed for other proteins. The blots show
representative gels while the bar graphs are composites summarized from all animals (n=4–9). (A) a-Syn and p-a-Syn were expressed relative to b-
actin used as a loading control. (B). p-Tau was probed using antibodies specific for pSer202, pSer262 and pSer396/404, and expressed relative to total
Tau used as loading control. (C). p-GSK-3b levels were probed using antibodies which recognize phosphorylation at Tyr216, and expressed relative to
total GSK-3b. (D) PP1, PP2A and PP2B levels were probed using specific antibodies and normalized to b-actin. Asterisks (*) indicate values significantly
different from wild-type animals (P,0.05). Student’s t-test was performed for all data.
doi:10.1371/journal.pone.0017953.g001
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antibody was used to stain striatal sections [Fig. 6B]. In the
striatum of Tg mice, large aggregates are present, in a peri-nuclear
fashion, with only small infrequent puncta seen in the WT
striatum.
Immunohistochemical co-localization and cell loss of
Substantia nigra
We also examined the Substania nigra of both A53T
transgenic and wild mice, in order to asses the effects of
tauopathy on neurons in this region of the brain. Fig. 7A shows
representative images of the distribution and co-localization of a-
Syn in TH positive neurons of the Substantia nigra of wild type and
A53T transgenic mice. White Boxes (Fig. 7A middle panel)
highlight single dopaminergic cells in far right panels which show
the presence or absence of a-Syn in TH positive cells in A53T
transgenic and wild type mice, respectively. A higher number of
TH positive cells have increases in the relative amounts of a-Syn
detected in A53T transgenic versus WT mice. This increase in
the amounts of a-Syn co-localizing with TH positive cells, being
greater in A53T transgenic Substantia nigra versus wild type, was
quantitatively assessed and verified using intensity correlation
analysis [32]. Dopaminergic cell loss was quantified using
methods described in legend to Fig. 7 [Fig. 7B]. The A53T
transgenic mouse shows a significant [P,0.05, n=3] decrease of
30.7% in TH positive DA neurons of the Substantia nigra versus
wild type. Such partial losses of DA neurons that we see in the
Substantia nigra of the A53T transgenic model, have also been
previously described in genetic, and toxin based mouse models of
PD [33,34].
Discussion
We describe for the first time the tauopathic changes
occurring in the striatum of the A53T a-Syn mutant hemizygous
mouse model of PD. We have previously demonstrated the
hyperphosphorylation of Tau in vivo in the MPTP-induced
neurotoxin mouse model of parkinsonism [24,27] and in vitro in
MPP
+-treated primary mesencephalic neurons [26], in SH-
SY5Y neuronal cells [24–25], as well as in postmortem PD
brains [23]. Our current studies show that a similar state of
tauopathy also exists in a well-studied animal model of PD, the
A53T a-Syn mutant mouse. Moreover, we also show that the
changes in the tauopathy-associated proteins, a-Syn, p-Tau and
p-GSK-3b, in the A53T mutant are similar to those which occur
in postmortem PD striata. In the present study we have used the
hemizygous A53T mouse, rather than the homozygous mouse,
which has reduced severity and delayed onset of the disease.
Moreover, we also used the 8 month old animal which is not yet
symptomatic and in which the parkinsonism is also known to be
less severe than in older animals. We nonetheless detected large
and robust increases in p-Tau levels, hyperphosphorylated at
Ser202, Ser262 and Ser396/404, which are the same major sites
of hyperphosphorylation seen in the pathology of AD [35,36]. In
addition, we also observed large increases in p-GSK-3b,t h e
major kinase known to hyperphosphorylate Tau at these
epitopes.
Only limited neurochemical studies have been conducted
demonstrating and identifying the epitopes of hyperphosphory-
lated Tau in postmortem tissues in PD brains or in animal models
of PD. A recent study found increased levels of Tau hyperpho-
sphorylated at Ser396 in synaptic-enriched fractions isolated from
the frontal cortex of PD patients [37]. In animal models of PD,
tauopathic changes have been observed in brainstem of symp-
tomatic A30P a-Syn mutant mice at pSer202 and pSer396/404
[38]. Another study using the neurotoxin rotenone to model
parkinsonism in rats, found immunoreactive Tau hyperpho-
sphorylated at Ser202/Thr205, Thr212/Ser214 and Ser396/404
[39].
An interesting aspect of our studies is that the overexpressed
A53T a-Syn seen in these animals was present as aggregates,
forming dimmers and trimers of the monomeric 17 kDa and the
12 kDa polypeptides in the Triton X 100-insoluble fractions, as
compared to wild-type animals. In addition, pSer396/404 Tau
and p-GSK-3b were also found to be present in the Triton X-100-
insoluble fractions, suggestive of their co-seggregation with a-Syn
aggregates. Indeed, in previous studies [27], we have demonstrat-
ed that a-Syn, pSer396/404 Tau and p-GSK-3b interact with
each other and are present in a trimeric complex, through stable
protein:protein interactions with one another. Although Tau and
a-Syn have distinct biological functions, in vitro studies have shown
that a-Syn can induce fibrillization of Tau, and vice versa, with the
A53T mutation accelerating and enhancing formation of fibrils as
compared to wildtype a-Syn [12].
In the present study, we also found enhanced levels of
pSer396/404 in cytoskeleton-free fractions, along with increased
levels of p-GSK-3b. It is now well established that upon
hyperphosphorylation, p-Tau dissociates from the microtubules
[35,36], and our results are consistent with this. The dissociation
of Tau from microtubules leads to their destabilization and
eventual collapse, resulting in neurodegeneration of neurons.
Thus, in a mouse model of AD, neurons expressing Tau
hyperphosphorylated at Ser202/Thr205 were more prone to
undergo degeneration [40]. Hyperphosphorylation at both
Ser262 and Ser396/404 has been shown to lead to reduced
binding of Tau to microtubules resulting in increased destabili-
zation of the microtubules [41] and, ultimately the collapse of the
cytoskeleton. The scenario presented by Tau hyperphosphory-
lated at Ser202, Ser262 and Ser396/404 in the A53T a-Syn
mutant is consistent with the degenerative changes observed in
dopaminergic neurons innervating the striatum in PD, which we
have shown earlier in a previous study [24]. Indeed, our results
show that upon hyperphosphorylation, all three epitopes of p-Tau
are exclusively present in the PIPES microtubule-free fraction
[see Fig. 4B]. Upon further aging of these mice, or in the
homozygous mouse where the disease is more severe, it is likely
that microtubule destabilization results.
An additional aspect of our results that is worth mentioning is
our findings regarding protein phosphatases. Thus, in neither the
A53T mice nor in human PD brains were we able to find changes
Figure 2. Postmortem PD brains show increased levels of a-Syn, p-GSK-3b and p-Tau at phosphorylation sites Ser202, Ser262 and
Ser396/404 similar to striatum in the 8 month-old A53T mice. Postmortem control and PD brain lysates were prepared and immunoblots
probed for (A) a-synuclein and p-a-synuclein, (B) phospho-specific Tau epitopes at Ser202, Ser262 and Ser396/404 and (C) p-GSK-3b. (D) PP1, PP2A
and PP2B levels were probed using specific antibodies and normalized to b-actin. Representative immunoblots from postmortem samples are shown.
b-actin levels were measured as loading controls. Increases in the level of a-synuclein and are normalized to b-actin and data are expressed as a
percent increase relative to amounts present in control, non-diseased brains (100%). Phospho-specific Tau and p-GSK-3b are expressed as a percent
increase with respect to non-diseased controls (100%) after normalization to total Tau and GSK-3b, respectively. Values are mean 6 SEM. Asterisks (*)
indicate values significantly different from age-matched control postmortem striata (p,0.05). Student’s t-test was performed for all data.
doi:10.1371/journal.pone.0017953.g002
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PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17953Figure 3. Triton X-100 solubilization of striatal lysates from A53T a-Syn mutant and age-matched control animals. Striatallysates from
A53T a-Synmutant miceand control, non-Tg mice [4 animals per group] were extracted withTritonX-100as described in Methods. Proteinsin TritonX-100-
soluble and Triton X-100-insoluble fractions were measured by Western blots. Blots show representative gels while the bar graphs are composites
summarizedfromallanimals,expressedaspercentofcontrol,non-Tgmice.(A)b-actinwasaddedasaloadingcontrol.(B)p-GSK-3bwasnormalizedtoGSK-
3bfromwithineachfractionontheblot.(C)pSer202,pSer262andPSer396/404wereallnormalizedtototalTauineachfraction,andb-actinwasaddedas a
loading control. *, P,0.05; **, P,0.01 and indicate values significantly different from wild-type animals. Student’s t-test was performed for all data.
doi:10.1371/journal.pone.0017953.g003
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linked to protein phosphtases. These findings are interesting, since
decreases in protein phosphatases could have lead to increases in
p-Tau levels.
We have also demonstrated here an increase in levels of p-
GSK-3b, autophosphorylated at Tyr216, which represents the
activated state of the kinase. GSK-3b is a proline-directed kinase
which has been shown to hyperphosphorylate Tau at several
known sites, including Ser202, Ser262 and Ser396/404 [42–45].
In neurons, GSK-3b’s activity is inhibited by N-terminal
phosphorylation at Ser9. Autophosphorylation at Tyr216 in
GSK-3b acts in opposition to this by increasing GSK-3b kinase
activity. In our study, p-GSK-3b activation mirrors increases in
p-Tau levels in the striatum of both animals and humans,
suggesting that this enzyme may be important in the genesis and
maintenance of PD in humans. Indeed, a recent study
demonstrated a strong linkage of two single nucleotide polymor-
phisms in the GSK-3b gene to sporadic PD [46]. Moreover, in
previous studies, we have found that a-Syn can recruit p-GSK-3b
through a direct physical protein:protein interaction to mediate
the hyperphosphorylation of Tau, and that activation of p-GSK-
3b by a-Syn precedes formation of p-Tau in vitro [27]. Our data
also shows an increase in GSK-3b-Ser9, which represents the
inactive form of the kinase. Interestingly, our findings showing
increases in both p-GSK-3b and GSK-3b-Ser9 are similar to that
seen reccently in Alzheimer’s disease, where GSK3b was found to
be phosphorylated to a similar extent at both the regulatory sites,
Ser9 and Tyr216 [47].
The current study also demonstrates in vivo co-localization and
accumulation of a-Syn, p-Tau and p-GSK-3b into aggregates, as
evidenced from immunohistochemical staining of striatal slices
from A53T mice. Moreover, we also observed a conformational
change in p-Tau, defined by antibody MC1, representing the
transition of p-Tau from soluble to aggregated filamentous Tau.
The folding of Tau into a paperclip-like structure, recognized by
MC1 antibodies, occurs when the amino acids at residues 7–9
interact with residues 312–342, and is one of the earliest
pathological alterations of Tau in Alzheimer disease, preceding
Figure 4. Binding of striatal proteins from A53T a-Syn mutant and wild-type non-Tg mice to cytoskeleton. Lysates from striata of
mutant and non-Tg mice [n=4 per group] were extracted in PIPES buffer and SDS buffer to obtain cytoskeleton-free and cytoskeleton-bound
fractions, as described in Methods. (A) a-Syn and p-GSK-3b were normalized to b-actin and GSK-3b, respectively, while (B) pSer396/404 was
normalized to total Tau. Results were expressed as percent of control non-Tg mice. Blots show representative gels while the bar graphs are
composites summarized from all animals. *, P,0.05; **, P,0.01 and indicate values significantly different from wild-type animals. Student’s t-test was
performed for all data.
doi:10.1371/journal.pone.0017953.g004
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the MC1 conformation is induced by hyperphosphorylation of
Tau at Ser199, Ser202, Thr205 and the PHF-1 sites [Ser396/
404], causing compaction of the paperclip structure [48].
Moreover, it has been shown that paperclip conformation of p-
Tau enhances its ability to aggregate to paired helical filaments
[48]. The presence of the aforementioned co-localized proteins in-
vivo and the observation of greater amounts of the aggregated
Figure 5. Immunohistochemical co-localization and distribution in A53T a-Syn and wildtype mice. Right panels constitute merged
image of left panels. (A). Striatum stained with a-Syn (Red) and PHF-1 Tau (Green) with DAPI as merged, and with single antibody(s). (B) Striatum
stained with a-Syn (Red) and p-GSK3b (Green) with DAPI as merged, and with single antibody(s). (C) Striatum stained with p-GSK-3b (Red) and PHF-1
(Green) with DAPI as merged, and with single antibody(s). Scale bar: 70 mm.
doi:10.1371/journal.pone.0017953.g005
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conclusion that such interactions or aggregations are indeed
pathogenic. The presence of neurotoxic aggregation correlates
with the loss of TH positive neurons in the striatum when
comparing A53T to wild type mice.
In conclusion, the present findings suggest that changes in Tau
metabolism may indeed be a common denominator in neurode-
generative diseases such as PD and AD. Despite differences in
their topographic distributions and phenotypic manifestations,
these diseases are linked by the progressive accumulation of
hyperphosphorylated Tau, activated GSK-3b and elevated levels
of a-Syn. Taken together, these findings highlight the potential
importance of targeting the tauopathic pathway in the therapeutic
management of diverse human neurodegenerative diseases,
including PD.
Materials and Methods
Materials
The antibodies used in this study are: anti-Tau MAB361 from
Millipore [Temecula, CA]; anti-Tau Neurofibrillary Tangles
Marker AHB0042 and anti-tau (pS262), Biosource Invitrogen
[Carlsbad, CA]; anti-a-Syn CAT# 610787, anti-GSK-3b
CAT# 612313 and anti-pGSK-3B [purified mouse anti-GSK-
3b (pY216) CAT # 612313], from BD Transduction Labs [San
Jose, CA]; anti-b-actin SC-1616, PP2B-Aa (C-20) SC-6123p-a-
Syn (Ser129) SC-135638 and PP1 (E-9) SC-7482 from Santa
Cruz Biotechnology, Inc. [Santa Cruz, CA]; The CP-13, PHF-1
and MC1 antibodies [recognizing Tau-Ser202, Tau-Ser396/404
and conformational-sensitive antibody, respectively] were gifts
from Dr. Peter Davies [New York]; anti-a-Tubulin T6074 from
Figure 6. TH and MC1 immunostaining in A53T a-Syn and wildtype mice. Immunohistochemical staining of tyrosine hydroxylase (TH, A) or
p-Tau using the MC1 antibody (B) was conducted as described in Methods, using DAPI to stain nuclei. Slides are shown at lowest magnification
(upper panels) to highest magnification (lower panels). (A). Dashed line represents demarcation of striatum with cortex (Cx). Scale bar: 70 mm.
(B). Asterisks indicate highlighted individual cells shown at higher magnification in lower panels. Scale Bar: 10 mm.
doi:10.1371/journal.pone.0017953.g006
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(Ser9) 9336 were from Cell Signaling Technology (Danvers,
Massachusetts); human p-a-Syn - Catalog #014-20281, Wako
Chemicals USA, Inc., Richmond, VA; mouse anti-Tyrosine
Hydroxylase Alexa Fluor 488 Conjugated Monoclonal
MAB5280X from Chemicon International [Billerica, MA];
rabbit polyclonal to MAP1 ab25954 from Abcam Inc. [Cam-
bridge, MA].
Figure 7. Immunohistochemical co-localization and counting of dopaminergic neurons in Substantia nigra. (A). Double immunostaining
of Substantia nigra stained for a-Syn (Red) and TH (Green) with DAPI. Panels left to right: 20X, 60X, with white boxes highlighted on left panels
indicate areas shown at higher magnification in far right panel(s) in wild type and A53T transgenic mouse brain. (B). Staining and counting of TH
(Green) positive dopaminergic neuronal cells within the Substantia nigra. Panels left to right: 20X (large panels), 60X (small panels), with white boxes
and asterisks highlighted on left panels indicating areas shown at higher magnification in far right panel(s) in wild type and A53T transgenic mouse
brain. Values are mean of (n=3 mice) Six Substantia nigra sections per WT and Tg mouse. P,0.05. Scale bar 10 uM. All images were taken on an
Olympus Fluoview FV300 using lenses: 20X N.A. 1.0, 60X N.A. 1.4. Images were processed in imageJ v1.44 (NIH) using the cell counter plug-in for
automated cell counting.
doi:10.1371/journal.pone.0017953.g007
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Mice used in accordance with the Georgetown University
Animal Care and Use Committee approval were bred and
maintained in University-approved animal facilities and handled
by trained personnel. Mice were group housed (2–5 animals/cage)
in temperature- and humidity-controlled rooms under 12 h light/
dark cycles and fed an ad-libitum diet of standard mouse chow.
Mice were originally obtained in breeding pairs from Jackson
laboratories (Bar Harbor, MA) to generate a stable breeding
colony. A breeding colony of transgenic mice carrying the hA53T
mutation driven by the mouse prion promoter was established
according to previously characterized mice [28]. Mice hemizygous
for the hA53T mutation were bred on a mixed C57BL/6J x C3H/
HeJ background to produce transgenic and non-transgenic litter
mates. In all cases, 2, 4 and 8 month-old transgenic mice were
directly compared with age-matched non-transgenic (wild-type)
litter mates. To identify transgenic mice, PCR amplifications were
performed on 1 mL of proteinase K digested (Promega, Madison,
WI) tail DNA samples using a sense (59-TGTAGGCTC-
CAAAACCAAGG-39) and an anti-sense primer (59-TGTCAG-
GATCCACAGGCATA-39). PCR reactions (30 mL) consisted of
10x NH4 buffer (Bioline, London, UK), 1.5 mM MgCl2, 0.05 mM
each dNTP, 0.4 pM of each primer, and 0.1 units of Taq DNA
polymerase (Bioline). Reactions were denatured at 95uC for 5
minutes and then subjected to 35 cycles of 95uC for 45 seconds,
61uC for 1 minute, 72uC for 1 minute, and 72uC for 2 minutes. A
30 mL aliquot from each reaction was analyzed by gel electro-
phoresis in a 1.5% agarose gel for the presence of a 248-base pair
band.
Postmortem tissue
Postmortem tissue was provided by the Sun Health Research
Institute Brain donation program (Sun City, AZ) and included
samples from PD cases that, antemortem, showed no evidence of
dementia (and neuropathologically confirmed to be absent of AD
pathology or cortical Lewy Bodies) and well characterized,
neurologically/neuropathologically normal controls. Clinical eval-
uation and neuropathological diagnoses of these cases have been
published in greater detail elsewhere [29]. The average postmor-
tem interval was ,3 hours. Data in this study were as follows: PD
patients: 4 male and 2 female, ages 84–90, with mean age of 85.3
years; control group, 3 males and 3 females, ages 78–89, with
mean age of 80.7 years. Since no gender differences were
observed, data were pooled together.
Tissues were homogenized in buffer containing 80 mM PIPES
(pH 6.8), 1 mM MgCl2, 2 mM EGTA. 0.1 mM EDTA, 0.1%
Triton X-100 and 30% glycerol. Lysates were incubated at 37uC
for 10 minutes prior to room temperature centrifugation at
14,0006g to separate soluble and insoluble fractions. Insoluble
fractions were re-suspended in 2% SDS, 5 mM EDTA, 5 mM
EGTA, 10% glycerol, 0.25 M Tris-HCl (pH 6.8) and sonicated
with a Branson Sonifier. The fractions were combined to obtain
total lysates and diluted with Laemmli buffer containing 5% b-
mercaptoethanol, 5% SDS and 1% sodium deoxycholate. Samples
were heated at 65uC for 1 hour and run on 10–20% Tris HCl
Criterion gels (Bio-Rad).
Preparation of Triton X-100 soluble and insoluble
fractions
The aggregation state of a-Syn was analyzed based on its
differential solubility in 1% Triton X-100, as described elsewhere
[30]. Briefly, tissues were extracted in buffer containing 20 mM
Tris-HCl, pH 7.4, 50 mM NaCl, 1% Triton X-100, protease
inhibitor cocktail tablets (Complete Mini, EDTA-free; Roche
Diagnostics GmbH, Germany) and phosphatase inhibitors
(Halt
TM Protease Inhibitor Cocktail; Pierce). Lysates were
incubated for 30 min on ice, followed by centrifugation at
15,0006g for 60 min at 4uC. The pellet and supernatant were
collected as the Triton X-100-insoluble and soluble fractions,
respectively. The Triton X-100-insoluble pellets were redissolved
in the previously described lysis buffer containing 2% SDS [30].
Extraction of tissues in PIPES-SDS buffer
To measure interaction of proteins with the cytoskeleton, mouse
striata were differentially extracted and separated into cytoskele-
ton-free and cytoskeleton-associated fractions as described previ-
ously [23]. Briefly, striata were homogenized in prewarmed
[37uC] extraction buffer (80 mM PIPES, pH 6.8, 1 mM MgCl2,
2 mM EGTA, 0.1 mM EDTA, 0.1% Triton X-100 and 30%
glycerol) containing protease inhibitors (Complete Mini, EDTA-
free; Roche Diagnostics GmbH, Germany) and phosphatase
inhibitors (Halt
TM Protease Inhibitor Cocktail; Pierce). After a
10 min incubation period at 37uC, lysates were centrifuged
(20 min, 14,0006g) at room temperature and the supernatant
removed; the supernatant contained soluble cytoskeletal-free
proteins. The pellet, containing the cytoskeletal-associated pro-
teins, was resuspended in 2% SDS, 5 mM EDTA, 10% glycerol,
0.25 mM Tris-HCl, pH 6.8 and sonicated with a Branson Sonifier
250.Sonication was done 3 times for 30 s at room temperature,
with cooling between bursts. Proteins in both fractions were
analyzed by Western blots.
Western Blot Analysis
Western blot analysis was performed as described elsewhere
[24,27]. Briefly, mouse striata were homogenized in RIPA buffer
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA)
containing 0.5% Triton X-100, 0.5% sodium deoxycholate, and
0.1% SDS in the presence of protease inhibitor cocktail tablets
(Complete Mini, EDTA-free; Roche Diagnostics GmbH, Ger-
many) and phosphatase inhibitor cocktail (Halt
TM Protease
Inhibitor Cocktail; Pierce). Lysates were left on ice for 20 minutes
and sonicated for 30 seconds with a Branson Sonifier. Lysates were
inverted at 4uC for 30 min, followed by centrifugation for 10 min
at 14,0006g and 4uC. Supernatants were collected and protein
concentrations were measured using the Lowry assay. Samples
were analyzed by Western blots on 10–20% Tris-HCl Criterion
gels (Bio-Rad), after blocking with 20 mM Tris-buffered saline,
pH 7.6 containing 0.1% Tween 20 (TBST) and 5% (wt/vol)
blotting grade blocker non-fat dry milk (Bio-Rad) for 1 hour at
room temperature. Western blots were developed with a wide
range of specific human Tau antibodies that recognize the protein
at different phosphorylation sites, including: CP13 (pS202) (1:500),
PHF-1 (pS396/404) (1:1000) and pS262 (1:500). Total Glycogen
Synthase Kinase-3b (GSK-3b) was probed for with mouse GSK-
3b antibody (1:500) and p-GSK-3b was probed for using mouse
phospho-specific (pY216) antibody (1:500). This antibody also
recognizes p-GSK-3a, detectable as a band visible above p-GSK-
3b; in our studies, only the lower band, corresponding to p-GSK-
3b was used to calculate for this protein. To probe for a-Syn,
samples were run on 10-20% Tris HCl Criterion gels (Bio-Rad)
and immunoblotted with mouse a-synuclein (1:500) antibody. All
proteins were normalized to total Tau (1:500) or b-actin. After
incubation for 2 hours at room temperature with HRP-conjugated
secondary antibodies (1:3000; Santa Cruz), proteins were revealed
by enhanced chemiluminescence (Perkin Elmer). Images were
scanned by Scanner EPSON Perfection V700 Photo and then
quantified using ImageJ.
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IHC analysis of mouse brain coronal sections was performed as
previously described [24], with slight modifications. Briefly, mouse
brains from 12 month old control wild-type and age-matched
A53T a-Syn mutant mice were perfused with 4% PFA, and
prepared in a sequential sucrose gradient, from 10% to a final
30% sucrose soak. Sections were washed, permeabilized, and
stained in the following manner. Each slice was washed 3 times in
1 mg/ml NaBr2, 1 X PBS pH 7.4, for 5 min at room temperature.
Following the NaBr2 auto-fluorescence quenching treatment, each
slice was washed 6 X, for 10 min in 1 X PBS pH 7.4, 1% Triton
X-100 followed by blocking for 1hr at room temperature in 1 X
PBS pH 7.4, 1% Triton X-100, 10% FCS. Antibodies were
conjugated primarily to the appropriate fluorophore as indicated
using the following reagents and manufacturer’s protocol:
Lighting-Link FITC #707-0030, Lighting-Link Rhodamine
#710-0030, Lighting-Link Texas Red #714-0030 (Novus Biolog-
icals Littleton, CO). Incubation with primary antibody occurred at
4uC, overnight in the dark, in blocking buffer using the following
concentrations for either single or dual staining with the following
fluorophore conjugated antibodies: anti-a-Syn, Texas Red 1:750;
Anti-p-GSK-3b (pY216), Texas Red; Anti-p-GSK-3b (pY216),
FITC 1:500; PHF-1, FITC 1:500; MC1, Rhodamine 1:500.
Following staining, each slice was washed 3 X in 1 X PBS pH 7.4,
1% Triton X-100 at room temperature, incubated for 30 min in
blocking buffer, and washed a final 3X in 1X PBS pH 7.4, 1%
Triton X-100. Stained slices were mounted to Fischer Scientific
Superfrost standard microscope slides using Fluoromount-DAPI.
Fluorescence images were captured using a laser scanning confocal
microscope (Olympus FV300). Paired images between WT and Tg
tissue for all figures were collected at the same laser power, gain,
and offset settings. Postcollection processing was performed using
ImageJ and applied uniformly to all paired images.
Statistical Analysis
Results were expressed as mean 6 S.E.M. and statistically
analyzed by the Student’s t test between two groups and analysis of
variance among multiple groups. Statistical significance was
accepted at the [P,0.05] level.
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